Food and Drug Administration (FDA)
NEWS
Shares of Menlo Park, Calif.-based Dermira jumped more than 10 percent this morning after the U.S. Food and Drug Administration (FDA) approved its therapy for people who have excessive underarm sweating.
Acceleron Pharma plans to seek regulatory approval next year for its investigational drug luspatercept. The treatment hit its Phase III endpoints.
With increased worries over the addictive nature of opioid-based pain treatments, more and more companies are focusing on the development of effective treatments without the addictive nature.
After failing to gain market share under the umbrella of Valeant Pharmaceuticals, Addyi is getting a relaunch at half the price.
Eli Lilly and Company announced the results of its COAST-W Phase III clinical trial of Taltz (ixekizumab) to treat Ankylosing Spondylitis (AS). The trial met both primary and major secondary endpoints.
Array BioPharma, Inc. secured approval for its combination treatment for BRAF-mutant metastatic melanoma.
Global Blood Therapeutics (GBT) reported the results of a review of Part A of its Phase III HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization) Study of voxelotor for sickle cell disease.
Pain Therapeutics stock plunged 70 percent after a U.S. Food and Drug Administration (FDA) advisory committee voted 14 to 3 against approval of its Remoxy ER for severe pain.
The Dementia Discovery Fund (DDF), a venture capital fund focused solely on dementia-related investments, completed $350 million of fundraising. The initial target was $200 million.
JOBS
IN THE PRESS